{"id":49367,"date":"2024-03-15T00:32:09","date_gmt":"2024-03-14T23:32:09","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=49367"},"modified":"2024-03-14T14:35:56","modified_gmt":"2024-03-14T13:35:56","slug":"lide-kteri-dostavaji-ivermektin-jsou-na-tom-lepe-ukazuje-studie","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2024\/03\/15\/lide-kteri-dostavaji-ivermektin-jsou-na-tom-lepe-ukazuje-studie\/","title":{"rendered":"Lid\u00e9, kte\u0159\u00ed dost\u00e1vaj\u00ed ivermektin, jsou na tom l\u00e9pe, ukazuje studie"},"content":{"rendered":"
<\/div>\n
\n
\n

Lid\u00e9, kte\u0159\u00ed byli pozitivn\u011b testov\u00e1ni na COVID-19 a byli l\u00e9\u010deni ivermektinem, se podle nov\u00e9 studie zotavili rychleji ne\u017e srovn\u00e1vac\u00ed skupina.<\/span><\/p>\n

Podle velk\u00e9 britsk\u00e9 studie byla u p\u0159\u00edjemc\u016f ivermektinu doba do uzdraven\u00ed, kterou sami uvedli, v pr\u016fm\u011bru o dva dny krat\u0161\u00ed.<\/span><\/p>\n

Krat\u0161\u00ed doba zotaven\u00ed byla statisticky v\u00fdznamn\u00e1.<\/span><\/p>\n

P\u0159\u00edjemci ivermektinu byli tak\u00e9 m\u00e9n\u011b \u010dasto hospitalizov\u00e1ni nebo zem\u0159eli: 1,6 procenta p\u0159\u00edjemc\u016f ivermektinu bylo hospitalizov\u00e1no nebo zem\u0159elo, ve srovn\u00e1n\u00ed se 4 procenty ve srovn\u00e1vac\u00ed skupin\u011b, kter\u00e9 se dostalo obvykl\u00e9 p\u00e9\u010de, kter\u00e1 se ve Spojen\u00e9m kr\u00e1lovstv\u00ed z velk\u00e9 \u010d\u00e1sti zam\u011b\u0159uje na l\u00e9\u010dbu p\u0159\u00edznak\u016f.<\/span><\/p>\n

P\u0159\u00edjemci ivermektinu tak\u00e9 t\u011b\u017eili ze sn\u00ed\u017een\u00ed z\u00e1va\u017en\u00fdch symptom\u016f a trval\u00e9ho zotaven\u00ed, podle studie.<\/span><\/p>\n

Studie\u00a0byla zve\u0159ejn\u011bna 29. \u00fanora v Journal of Infection\u00a0<\/span>.<\/span><\/a><\/p>\n

Studie zahrnovala otev\u0159enou studii 2 157 lid\u00ed, kte\u0159\u00ed dost\u00e1vali ivermektin, a 3 256 lid\u00ed, kte\u0159\u00ed dost\u00e1vali obvyklou p\u00e9\u010di od 23. \u010dervna 2021 do 1. \u010dervence 2022.\u00a0\u00da\u010dastn\u00edci byli n\u00e1hodn\u011b vybr\u00e1ni a hl\u00e1sili symptomy a uzdraven\u00ed.<\/span><\/p>\n

V\u011bdci tvrd\u00ed, \u017ee v\u00fdsledky nepodporuj\u00ed pou\u017eit\u00ed ivermektinu<\/span><\/p>\n

Auto\u0159i, v\u010detn\u011b Christophera Butlera, profesora na Oxfordsk\u00e9 univerzit\u011b a spoluvedouc\u00edho studie, pozitivn\u00ed v\u00fdsledky \u010d\u00e1ste\u010dn\u011b bagatelizuj\u00ed, proto\u017ee pom\u011br rizika 1,14 byl ni\u017e\u0161\u00ed ne\u017e pom\u011br 1,2, kter\u00fd auto\u0159i stanovili jako smyslupln\u00fd.\u00a0Pom\u011bry rizik se pou\u017e\u00edvaj\u00ed k ur\u010den\u00ed, zda m\u00e1 l\u00e9\u010dba p\u0159\u00ednos.<\/span><\/p>\n

Auto\u0159i se tak\u00e9 zam\u011b\u0159ili na nedostatek rozd\u00edl\u016f v po\u010dtu dn\u00ed, kdy se \u00fa\u010dastn\u00edci c\u00edtili nemocn\u00ed v posledn\u00edch dvou t\u00fddnech, dopad na pr\u00e1ci a pravd\u011bpodobnost vyu\u017eit\u00ed syst\u00e9mu zdravotn\u00ed p\u00e9\u010de t\u0159i, \u0161est a 12 m\u011bs\u00edc\u016f pot\u00e9, co se l\u00e9\u010dili.<\/span><\/p>\n

\u201eCelkov\u011b tyto v\u00fdsledky ukazuj\u00ed mal\u00fd p\u0159\u00ednos, pokud jde o trv\u00e1n\u00ed symptom\u016f, nepodporuj\u00ed v\u0161ak pou\u017eit\u00ed ivermektinu k l\u00e9\u010db\u011b COVID-19 u p\u0159ev\u00e1\u017en\u011b o\u010dkovan\u00e9 populace v d\u00e1vce a d\u00e9lce, kterou jsme pou\u017eili,\u201c uvedli auto\u0159i.<\/span><\/p>\n

V\u00fdzkum byl financov\u00e1n britskou vl\u00e1dou.<\/span><\/p>\n

St\u0159ety z\u00e1jm\u016f zahrnovaly jednoho v\u00fdzkumn\u00edka, kter\u00fd obdr\u017eel granty od farmaceutick\u00fdch spole\u010dnost\u00ed, v\u010detn\u011b AstraZeneca, a dal\u0161\u00ed autory, kte\u0159\u00ed obdr\u017eeli granty od University of Oxford.<\/span><\/strong><\/p>\n

Studie nazvan\u00e1 PRINCIPLE byla v\u011bdci nab\u00edzena jako \u201enejv\u011bt\u0161\u00ed klinick\u00e1 studie na sv\u011bt\u011b s potenci\u00e1ln\u00ed l\u00e9\u010dbou COVID-19 pro zotaven\u00ed doma a v jin\u00fdch prost\u0159ed\u00edch mimo nemocnici\u201c.<\/span><\/p>\n

\u201eIvermektin je dostupn\u00fd po cel\u00e9m sv\u011bt\u011b, pou\u017e\u00edv\u00e1 se k l\u00e9\u010db\u011b mnoha dal\u0161\u00edch infek\u010dn\u00edch onemocn\u011bn\u00ed, je to tedy dob\u0159e zn\u00e1m\u00fd l\u00e9k s dobr\u00fdm bezpe\u010dnostn\u00edm profilem a na z\u00e1klad\u011b prvn\u00edch slibn\u00fdch v\u00fdsledk\u016f n\u011bkter\u00fdch studi\u00ed se ji\u017e v n\u011bkolika zem\u00edch \u0161iroce pou\u017e\u00edv\u00e1 k l\u00e9\u010db\u011b COVID. -19.\u201c \u0159ekl Dr.\u00a0Christopher Butler, profesor na Oxfordsk\u00e9 univerzit\u011b a vedouc\u00ed studie, kdy\u017e bylo ozn\u00e1meno, \u017ee bude studov\u00e1n ivermektin.\u00a0\u201eZa\u0159azen\u00edm ivermektinu do rozs\u00e1hl\u00e9 studie, jako je PRINCIPLE, douf\u00e1me, \u017ee poskytneme smyslupln\u00e9 d\u016fkazy o tom, jak \u00fa\u010dinn\u00e1 je l\u00e9\u010dba proti COVID-19 a zda m\u00e1 n\u011bjak\u00e9 v\u00fdhody nebo nev\u00fdhody.<\/span>
\nL\u00e9ka\u0159i mluv\u00ed<\/span><\/p>\n

Dr.\u00a0Pierre Kory, americk\u00fd l\u00e9ka\u0159, kter\u00fd se na studii nepod\u00edlel, uvedl, \u017ee auto\u0159i nespravedliv\u011b bagatelizovali zlep\u0161en\u00ed ivermektinu p\u0159i zotaven\u00ed z COVID-19.<\/span><\/p>\n

\u201ePRINCIPLE byla hluboce pozitivn\u00ed studie, kter\u00e1 byla m\u00edsto toho analyzov\u00e1na a prezentov\u00e1na jako negativn\u00ed,\u201c napsal Dr.\u00a0Kory, kter\u00fd dlouho obhajoval ivermektin jako l\u00e9\u010dbu COVID-19, v eseji.<\/span><\/p>\n

Obvinil autory ze \u201estatistick\u00e9 \u0161ikanov\u00e1n\u00ed\u201c za pou\u017eit\u00ed v\u00fdchoz\u00edho pom\u011bru rizika (HR), i kdy\u017e v jin\u00fdch \u010d\u00e1stech studie PRINCIPLE \u017e\u00e1dn\u00e1 takov\u00e1 hodnota nebyla pou\u017eita.<\/span><\/p>\n

\u201ePom\u011br rizik nevy\u017eaduje p\u0159edem stanovenou \u00farove\u0148.\u00a0Pokud je HR nad 1,0 a je statisticky v\u00fdznamn\u00fd, je to robustn\u00ed v\u00fdsledek,\u201c \u0159ekl.<\/span><\/p>\n

Pozitivn\u00ed v\u00fdsledky by m\u011bly b\u00fdt tak\u00e9 interpretov\u00e1ny ve sv\u011btle skute\u010dnosti, \u017ee pacienti dost\u00e1vaj\u00ed pouze jednu d\u00e1vku denn\u011b po dobu t\u0159\u00ed dn\u016f a jsou pou\u010deni, aby p\u0159ed u\u017eit\u00edm ivermektinu nejedli.<\/span><\/p>\n

Dr.\u00a0Butler a jeho spoluauto\u0159i uvedli, \u017ee \u201edv\u011b hodiny p\u0159ed nebo po pod\u00e1n\u00ed by se nem\u011blo j\u00edst \u017e\u00e1dn\u00e9 j\u00eddlo\u201c, a\u010dkoli p\u0159edchoz\u00ed studie uk\u00e1zaly, \u017ee u\u017e\u00edv\u00e1n\u00ed ivermektinu s j\u00eddlem zvy\u0161uje plazmatick\u00e9 koncentrace.<\/span><\/p>\n

\u00da\u010dastn\u00edci dostali ivermektin v pr\u016fm\u011bru p\u011bt dn\u00ed po objeven\u00ed se symptom\u016f, co\u017e n\u011bkte\u0159\u00ed pova\u017euj\u00ed za p\u0159\u00edli\u0161 pozd\u011b na to, aby m\u011blo v\u00fdznamn\u00fd \u00fa\u010dinek.\u00a0Podle meta-regrese studi\u00ed s ivermektinem je ivermektin nej\u00fa\u010dinn\u011bj\u0161\u00ed, kdy\u017e je pod\u00e1n do 24 hodin od n\u00e1stupu symptom\u016f.<\/span><\/p>\n

Dr.\u00a0Butler na \u017e\u00e1dosti o koment\u00e1\u0159 nereagoval.<\/span><\/p>\n

Jin\u00e9 studie uk\u00e1zaly, \u017ee ivermektin je \u00fa\u010dinn\u00fd proti COVID-19.\u00a0Droga, obvykle pou\u017e\u00edvan\u00e1 v boji proti mal\u00e1rii, rozd\u011bluje v\u011bdu od roku 2020, kdy ji l\u00e9ka\u0159i po cel\u00e9m sv\u011bt\u011b za\u010dali pou\u017e\u00edvat k l\u00e9\u010db\u011b COVID-19.<\/span><\/p>\n

Jin\u00e9 studie, v\u010detn\u011b jedn\u00e9 americk\u00e9, uk\u00e1zaly, \u017ee ivermektin nezkracuje dobu zotaven\u00ed.<\/span><\/p>\n

Dr.\u00a0David Boulware, dal\u0161\u00ed americk\u00fd l\u00e9ka\u0159, kter\u00fd pomohl prov\u00e9st tuto studii, argumentoval proti antivirotiku, kter\u00e9 se n\u011bkdy pou\u017e\u00edv\u00e1 k l\u00e9\u010db\u011b COVID-19.<\/span><\/p>\n

\u201eMolnupiravir tak\u00e9 vedl k o dva dny rychlej\u0161\u00edmu zlep\u0161en\u00ed symptom\u016f ve srovn\u00e1n\u00ed se \u201astandardn\u00ed l\u00e9\u010dbou\u2018, ale ve dvojit\u011b zaslepen\u00e9 studii nebyl \u017e\u00e1dn\u00fd p\u0159\u00ednos,\u201c \u0159ekl Dr.\u00a0Boulware na X. \u201ePlacebo efekt ovliv\u0148uje symptomy, kter\u00e9 si sami hl\u00e1sili.<\/span><\/p>\n<\/div>\n<\/div>\n

\n
\n

ZDROJ<\/a><\/span><\/h3>\n

 <\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Lid\u00e9, kte\u0159\u00ed byli pozitivn\u011b testov\u00e1ni na COVID-19 a byli l\u00e9\u010deni ivermektinem, se podle nov\u00e9 studie…<\/p>\n","protected":false},"author":2,"featured_media":2321,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[5785,518,839],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/49367"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=49367"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/49367\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/2321"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=49367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=49367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=49367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}